Stay updated with breaking news from Embryonic Ectoderm Development. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
SUZHOU, China and ROCKVILLE, Md., May 15, 2024 /PRNewswire/ -- Ascentage Pharma , a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B , and...
― Completed enrollment in the Phase 3 REACH trial of losmapimod in facioscapulohumeral muscular dystrophy (FSHD); expect to report topline data in...
CAMBRIDGE, Mass., Aug. 22, 2023 -- Fulcrum Therapeutics, Inc.® , a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today...
Fulcrum Therapeutics, Inc. (FULC) announced Tuesday that the U.S. Food and Drug Administration has lifted the clinical hold on the Investigational New Drug or IND application for FTX-6058 for the potential treatment of sickle-cell disease or SCD.
― Appointed Alex C. Sapir CEO & President, effective July 1st, 2023 ― ― On track to complete enrollment in Phase 3 REACH trial of losmapimod in facioscapulohumeral... | May 15, 2023